Adocia, a clinical biopharmaceutical company focused on developing innovative formulations of approved proteins for the treatment of diabetes, announced Dr Stanislav Glezer has joined the Company as Chief Medical Officer.
In his new position, Dr Glezer will oversee clinical development and lead Adocia’s medical strategy.
Dr Glezer received his medical degree from Moscow State University of Medicine & Dentistry and a graduate diploma in clinical research from McGill University. Dr Glezer also holds an MBA from California Coast University.
Before joining Adocia, he served as Vice President, Medical Affairs at Novo Nordisk.
Previously, he held several positions of increasing responsibility at Sanofi, including Global Leader for Toujeo Project, Vice President Evidence Value and Access, and Vice President Medical Affairs.
In his new capacity, Dr Glezer will be responsible for designing and executing the clinical development plan for the Adocia portfolio of novel treatments for diabetes. This broad set of programmes ranges from preclinical to pre-phase three assets and notably includes
- BioChaperone Lispro, an ultra-rapid prandial insulin (ready to enter Phase 3)
- BioChaperone Combo, a combination of prandial and basal insulin (Phase 2)
- BioChaperone Glucagon, an aqueous ready-to-use formulation of human glucagon (Phase 1)
- BioChaperone Prandial Combo, combinations of prandial insulins and pramlintide and exenatide (preclinical stage)
Gérard Soula, Chairman and CEO at Adocia, said: “[Dr Glezer’s] outstanding track-record in clinical development, product launch and medical affairs with industry leading companies in diabetes is a significant asset for Adocia.
“In particular, as a Global Leader for Toujeo he has garnered invaluable expertise on the development and launch of an innovative formulation of an approved insulin. These skills are extremely relevant to our innovative projects based on BioChaperone technology.”
Dr Glezer said: “I am confident that the BioChaperone formulation strategy should yield improvements in single agent and combination products, while supporting a competitive price strategy that enables broader access for patients around the world.”
